Page 16 - linda_borst

22 Street, S. E. et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer
cells and gammadelta T cells. J Exp Med 199, 879-884, doi:10.1084/jem.20031981 (2004).
23 Lanier, L. L. NK cell receptors. Annu Rev Immunol 16, 359-393, doi:10.1146/annurev.
immunol.16.1.359 (1998).
24 Brunet, J. F. et al. A new member of the immunoglobulin superfamily--CTLA-4. Nature 328, 267-
270, doi:10.1038/328267a0 (1987).
25 Krummel, M. F. & Allison, J. P. CD28 and CTLA-4 have opposing effects on the response of T cells
to stimulation. J Exp Med 182, 459-465, doi:10.1084/jem.182.2.459 (1995).
26 Lee, K. M. et al. Molecular basis of T cell inactivation by CTLA-4. Science 282, 2263-2266,
doi:10.1126/science.282.5397.2263 (1998).
27 Ishida, Y., Agata, Y., Shibahara, K. & Honjo, T. Induced Expression of Pd-1, a Novel Member of
the Immunoglobulin Gene Superfamily, Upon Programmed Cell-Death. Embo J 11, 3887-3895,
doi:DOI 10.1002/j.1460-2075.1992.tb05481.x (1992).
28 Nishimura, H., Nose, M., Hiai, H., Minato, N. & Honjo, T. Development of lupus-like autoimmune
diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
Immunity 11, 141-151, doi:10.1016/s1074-7613(00)80089-8 (1999).
29 Freeman, G. J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family
member leads to negative regulation of lymphocyte activation. J Exp Med 192, 1027-1034,
doi:10.1084/jem.192.7.1027 (2000).
30 Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity’s roles
in cancer suppression and promotion. Science 331, 1565-1570, doi:10.1126/science.1203486
(2011).
31 Beatty, G. L. & Gladney, W. L. Immune escape mechanisms as a guide for cancer immunotherapy.
Clin Cancer Res 21, 687-692, doi:10.1158/1078-0432.Ccr-14-1860 (2015).
32 van der Burg, S. H., Arens, R., Ossendorp, F., van Hall, T. & Melief, C. J. Vaccines for established
cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer 16, 219-233,
doi:10.1038/nrc.2016.16 (2016).
33 Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat
Rev Cancer 21, 360-378, doi:10.1038/s41568-021-00346-0 (2021).
34 Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of
immune evasion. Nat Med 8, 793-800, doi:10.1038/nm730 (2002).
35 Lee, S. J. et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and
IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 580, 755-762, doi:10.1016/j.
febslet.2005.12.093 (2006).
36 Leach, D. R., Krummel, M. F. & Allison, J. P. Enhancement of antitumor immunity by CTLA-4
blockade. Science 271, 1734-1736, doi:10.1126/science.271.5256.1734 (1996).
37 Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl
J Med 363, 711-723, doi:10.1056/NEJMoa1003466 (2010).
38 Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N
Engl J Med 364, 2517-2526, doi:10.1056/NEJMoa1104621 (2011).
39 Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder
cancer. Nature 515, 558-562, doi:10.1038/nature13904 (2014).
40 Brahmer, J. et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung
Cancer. N Engl J Med 373, 123-135, doi:10.1056/NEJMoa1504627 (2015).

14 CHAPTER 1